ArticleAnnals of surgical oncology2026
Immunochemotherapy Versus Chemoradiotherapy Followed by Conversion Surgery for Initially Unresectable Stage cT4 Esophageal Squamous Cell Carcinoma.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemoradiotherapy has proven effective in enabling conversion surgery (CS). However, the priority of immunochemotherapy compared with chemoradiotherapy as induction therapy for initially unresectable cT4 esophageal squamous cell carcinoma (ESCC) remains unclear. We aimed to compare the survival outcomes of CS following induction immunochemotherapy (iICT) versus induction chemoradiotherapy (iCRT) in these patients.
methodsThis multi-institutional retrospective cohort study included initially unresectable cT4 ESCC patients who underwent CS after iICT or iCRT between 2019 and 2022. Overall survival (OS) and disease-free survival (DFS) were analyzed using the Kaplan-Meier method and the log-rank-test. Univariable and multivariable analyses for prognostic factors were performed.
resultsIn total, 118 patients were included: 43 in the iICT group and 75 in the iCRT group. There were no significant differences between the two groups in terms of pathological complete response rates (P = 0.637) or R0 resection rates (P = 0.885). The iICT group had a lower rate of postoperative overall recurrence (P = 0.005) and distant metastasis (P = 0.015) than the iCRT group. The OS (1-year: 90.4% vs. 76.0%; 3-year: 77.3% vs. 54.9%, P = 0.027) and DFS (1-year: 85.4% vs. 58.7%; 3-year: 73.1% vs. 39.0%, P = 0.001) rates were significantly higher in the iICT group than in the iCRT group. Multivariable Cox analysis demonstrated that the iICT regimen was independently associated with improved OS and DFS.
conclusionsiICT combined with CS was a safe and manageable treatment option and was associated with improved OS and DFS in patients with initially unresectable cT4 ESCC.
Indexed as
Identifiers
41843299What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.